194 related articles for article (PubMed ID: 25155936)
1. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
Gravia A; Chondrou V; Sgourou A; Papantoni I; Borg J; Katsila T; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2014 Jul; 15(10):1355-64. PubMed ID: 25155936
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and therapeutics of hemoglobinopathies.
Patrinos GP; Grosveld FG
Hemoglobin; 2008; 32(1-2):229-36. PubMed ID: 18275000
[TBL] [Abstract][Full Text] [Related]
3. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
4. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
5. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
6. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
Chondrou V; Kolovos P; Sgourou A; Kourakli A; Pavlidaki A; Kastrinou V; John A; Symeonidis A; Ali BR; Papachatzopoulou A; Katsila T; Patrinos GP
Hum Genomics; 2017 Oct; 11(1):24. PubMed ID: 29061162
[TBL] [Abstract][Full Text] [Related]
7. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
8. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
9. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
[TBL] [Abstract][Full Text] [Related]
11. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
Chalikiopoulou C; Tavianatou AG; Sgourou A; Kourakli A; Kelepouri D; Chrysanthakopoulou M; Kanelaki VK; Mourdoukoutas E; Siamoglou S; John A; Symeonidis A; Ali BR; Katsila T; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2016 Mar; 17(4):393-403. PubMed ID: 26895070
[TBL] [Abstract][Full Text] [Related]
12. Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.
Fertrin KY; Costa FF
Expert Rev Hematol; 2010 Aug; 3(4):443-58. PubMed ID: 21083035
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications.
Gambari R; Waziri AD; Goonasekera H; Peprah E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673849
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
15. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies.
Perrine SP; Pace BS; Faller DV
Hematol Oncol Clin North Am; 2014 Apr; 28(2):233-48. PubMed ID: 24589264
[TBL] [Abstract][Full Text] [Related]
16. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
17. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of hemoglobin: its application to sickle cell anemia and thalassemia.
Kan YW
Schweiz Med Wochenschr Suppl; 1991; 43():51-4. PubMed ID: 1726857
[TBL] [Abstract][Full Text] [Related]
19. Study on the Role of Polymorphisms of the SOX-6 and MYB Genes and Fetal Hemoglobin Levels in Sicilian Patients with β-Thalassemia and Sickle Cell Disease.
Listì F; Sclafani S; Agrigento V; Barone R; Maggio A; D'Alcamo E
Hemoglobin; 2018 Mar; 42(2):103-107. PubMed ID: 30200835
[TBL] [Abstract][Full Text] [Related]
20. Genetic studies of fetal hemoglobin in the Arab-Indian haplotype sickle cell-β(0) thalassemia.
Alsultan A; Ngo D; Bae H; Sebastiani P; Baldwin CT; Melista E; Suliman AM; Albuali WH; Nasserullah Z; Luo HY; Chui DH; Steinberg MH; Al-Ali AK
Am J Hematol; 2013 Jun; 88(6):531-2. PubMed ID: 23483609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
